Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | CH3O6P2.3Na.4H2O |
| Molecular Weight | 314.0089 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O.O.O.O.[Na+].[Na+].[Na+].OP([O-])(=O)CP([O-])([O-])=O
InChI
InChIKey=NPZGSDFOXPZGAQ-UHFFFAOYSA-K
InChI=1S/CH6O6P2.3Na.4H2O/c2-8(3,4)1-9(5,6)7;;;;;;;/h1H2,(H2,2,3,4)(H2,5,6,7);;;;4*1H2/q;3*+1;;;;/p-3
DescriptionCurator's Comment: Description was created based on several sources, including:
https://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=9635
Curator's Comment: Description was created based on several sources, including:
https://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=9635
Medronic acid (conjugate base, medronate) is a diagnostic agent that is used in complex with technetium Tc-99m for imaging delineate areas of altered osteogenesis. Upon administration the complex binds to hydroxyapatite crystals in bone.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: Hydroxyapatite crystals in bone |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Diagnostic | CIS-MDP Approved UseTechnetium Tc 99m Medronate Injection may be used as a bone imaging agent to delineate areas of altered osteogenesis. Launch Date1979 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Cytosolic acidification as a signal mediating hyperosmotic stress responses in Dictyostelium discoideum. | 2001 |
|
| Quantitative studies of bone with the use of 18F-fluoride and 99mTc-methylene diphosphonate. | 2001 Jan |
|
| Special feature: radiological case of the month. Congenital syphilis presenting as osteomyelitis with normal radioisotope bone scan. | 2001 May |
|
| Factors influencing blood flow in the equine digit and their effect on uptake of 99m technetium methylene diphosphonate into bone. | 2001 Nov |
|
| Determination of the casein content in bovine milk by 31P-NMR. | 2002 Aug |
|
| Synthesis of stable analogues of thiamine di- and triphosphate as tools for probing a new phosphorylation pathway. | 2002 Oct 18 |
|
| Escherichia coli response to exogenous pyrophosphate and analogs. | 2003 |
|
| Collagen crosslink excretion and staging of oral cancer. | 2003 Apr 7 |
|
| Infecton: a 99mTc-ciprofloxacin radiopharmaceutical for the detection of bone infection. | 2003 Feb |
|
| Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease. | 2003 Feb 1 |
|
| Signal enhancement through heteronuclear polarisation transfer in in-vivo 31P MR spectroscopy of the human brain. | 2003 Jul |
|
| Follow-up of collagen crosslink excretion in patients with oral squamous cell carcinoma and analysis of tissue samples. | 2003 Nov 3 |
|
| Gelatin sheet incorporating basic fibroblast growth factor enhances sternal healing after harvesting bilateral internal thoracic arteries. | 2003 Oct |
|
| Solid state coordination chemistry: one-, two-, and three-dimensional materials constructed from molybdophosphonate subunits linked through binuclear copper tetra-2-pyridylpyrazine groups. | 2003 Oct 20 |
|
| [A comparison of planar scintigraphy and MRI in the screening of skeletal metastases]. | 2003 Sep |
|
| Shoulder girdle neoplasms mimicking frozen shoulder syndrome. | 2003 Sep-Oct |
|
| Cervical involvement in juvenile-onset ankylosing spondylitis with bone scintigraphy. | 2004 May |
|
| [Menopause in 2004: "hormone replacement therapy" is not what it used to be anymore]. | 2004 Nov |
|
| Calix[4]arene methylenebisphosphonic acids as calf intestine alkaline phosphatase inhibitors. | 2004 Nov 7 |
|
| Synthesis of acyloxymethyl ester prodrugs of the transferable protein farnesyl transferase substrate farnesyl methylenediphosphonate. | 2004 Oct 4 |
|
| 31P MRS analysis of the phospholipid composition of normal human peripheral blood mononuclear cells (PBMC). | 2005 |
|
| Voltammetry as a virtual potentiometric sensor in modelling of a metal-ligand system and refinement of stability constants. Part 4. An electrochemical study of NiII complexes with methylene diphosphonic acid. | 2005 Dec |
|
| [A cationic cluster of amino acid residues of inorganic pyrophosphatase from Escherichia coli as a possible site of effector binding]. | 2005 May-Jun |
|
| Biochemical and imaging alterations of renal bone disease in newly detected predialysis and on maintenance dialysis patients. | 2005 Oct |
|
| Synthesis and antiviral evaluation of alkoxyalkyl esters of phosphonopropoxymethyl-guanine and phosphonopropoxymethyl-diaminopurine. | 2006 |
|
| Development of a novel 99mTc-chelate-conjugated bisphosphonate with high affinity for bone as a bone scintigraphic agent. | 2006 Dec |
|
| Use of scintigraphy for diagnosis of equine paranasal sinus disorders. | 2006 Jan |
|
| Characterization of industrial alkylpolyphosphonates by infusion electrospray ionization-ion trap mass spectrometry with identification of the impurities by tandem capillary zone electrophoresis. | 2006 Jan |
|
| Acid resistance of erbium-doped yttrium aluminum garnet laser-treated and phosphoric acid-etched enamels. | 2006 Nov |
|
| Novel chikungunya virus variant in travelers returning from Indian Ocean islands. | 2006 Oct |
|
| Is there a role of whole body bone scan in early stages of non small cell lung cancer patients. | 2006 Oct-Dec |
|
| Nuclear medicine methods for evaluation of skeletal infection among other diagnostic modalities. | 2006 Sep |
|
| Three-level bilateral pediculolysis following osteoporotic lumbar compression fracture. | 2006 Sep-Oct |
|
| Safety considerations with bisphosphonates for the treatment of osteoporosis. | 2007 |
|
| Rapid characterization of alkylpolyphosphonates by CZE with indirect photometric and mass spectrometric detection. | 2007 Feb |
|
| ATP as effector of inorganic pyrophosphatase of Escherichia coli. The role of residue Lys112 in binding effectors. | 2007 Jan |
|
| PET-CT in pediatric Langerhans cell histiocytosis. | 2007 Jul |
|
| Alpha-substituted phosphonate analogues of lysophosphatidic acid (LPA) selectively inhibit production and action of LPA. | 2007 May |
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
207556-02-3
Created by
admin on Sat Dec 16 09:12:32 GMT 2023 , Edited by admin on Sat Dec 16 09:12:32 GMT 2023
|
PRIMARY | |||
|
BTP52VM2H0
Created by
admin on Sat Dec 16 09:12:32 GMT 2023 , Edited by admin on Sat Dec 16 09:12:32 GMT 2023
|
PRIMARY | |||
|
71308443
Created by
admin on Sat Dec 16 09:12:32 GMT 2023 , Edited by admin on Sat Dec 16 09:12:32 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD
